BC
SLRN

Bridgefront Capital’s ACELYRIN SLRN Stock Holding History

Bridgefront Capital’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,249
Closed -$83.9K – 538
2023
Q4 		$83.9K Buy
+11,249
New +$96K 0.06% 344

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Bridgefront Capital's SLRN Position: Q1 2024 in Review

Bridgefront Capital sold out of ACELYRIN (SLRN) in Q1 2024, closing a stake of 11,249 shares — an estimated $83.9K sold.

Bridgefront Capital first reported a position in SLRN in Q4 2023 and held it in 1 quarter. The position peaked at $83.9K in Q4 2023. 109 funds tracked by Wall St. Rank hold SLRN as of Q1 2024.

  • Bridgefront Capital reported no remaining ACELYRIN position as of Q1 2024 after selling out during the quarter.
  • Bridgefront Capital sold 11,249 ACELYRIN shares in Q1 2024, an estimated $83.9K.
  • Bridgefront Capital first reported a position in ACELYRIN in Q4 2023 and held it in 1 quarter.
  • Bridgefront Capital's ACELYRIN position peaked at $83.9K in Q4 2023.
  • 109 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2024.

Based on Bridgefront Capital's 13F filing for Q1 2024, filed 15 May 2024.